Nathalie Spielewoy
Overview
Explore the profile of Nathalie Spielewoy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
314
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pott C, Jurinovic V, Trotman J, Kehden B, Unterhalt M, Herold M, et al.
J Clin Oncol
. 2023 Dec;
42(5):550-561.
PMID: 38096461
Purpose: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier:...
2.
Morschhauser F, Feugier P, Flinn I, Gasiorowski R, Greil R, Illes A, et al.
Blood
. 2021 Feb;
137(5):600-609.
PMID: 33538797
The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L)...
3.
Zinzani P, Flinn I, Yuen S, Topp M, Rusconi C, Fleury I, et al.
Blood
. 2020 Aug;
136(23):2628-2637.
PMID: 32785666
This open-label phase 2 study (CONTRALTO) assessed the safety and efficacy of BCL-2 inhibitor venetoclax (VEN) plus rituximab (R), and VEN plus bendamustine (B) and R, vs B + R...
4.
Pott C, Sehn L, Belada D, Gribben J, Hoster E, Kahl B, et al.
Leukemia
. 2019 Aug;
34(2):522-532.
PMID: 31462735
We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus...
5.
Klanova M, Oestergaard M, Trneny M, Hiddemann W, Marcus R, Sehn L, et al.
Clin Cancer Res
. 2019 May;
25(15):4634-4643.
PMID: 31053601
Purpose: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood...
6.
Spielewoy N, Guaderrama M, Wohlschlegel J, Ashe M, Yates 3rd J, Wittenberg C
Eukaryot Cell
. 2010 Feb;
9(4):592-601.
PMID: 20154027
Npr2, a putative "nitrogen permease regulator" and homolog of the human tumor suppressor NPRL2, was found to interact with Grr1, the F-box component of the SCF(Grr1) (Skp1-cullin-F-box protein complex containing...
7.
Jourdain I, Spielewoy N, Thompson J, Dhut S, Yates J, Toda T
Biochem J
. 2009 Feb;
420(2):169-77.
PMID: 19243310
The F-box domain is a degenerated motif consisting of approximately 40 amino acid residues that specifically bind Skp1, a core component of the SCF (Skp1-Cdc53/Cullin 1-F-box protein) ubiquitin ligase. Recent...
8.
Spielewoy N, Flick K, Kalashnikova T, Walker J, Wittenberg C
Mol Cell Biol
. 2004 Oct;
24(20):8994-9005.
PMID: 15456873
SCFGrr1, one of several members of the SCF family of E3 ubiquitin ligases in budding Saccharomyces cerevisiae, is required for both regulation of the cell cycle and nutritionally controlled transcription....
9.
Flick K, Spielewoy N, Kalashnikova T, Guaderrama M, Zhu Q, Chang H, et al.
Mol Biol Cell
. 2003 Aug;
14(8):3230-41.
PMID: 12925759
In budding yeast, HXT genes encoding hexose permeases are induced by glucose via a mechanism in which the F box protein Grr1 antagonizes activity of the transcriptional repressor Rgt1. Neither...